Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) CFO Alisha Charlton sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $40.02, for a total transaction of $40,020.00. Following the completion of the transaction, the chief financial officer now owns 15,339 shares of the company's stock, valued at $613,866.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Pro-Dex Trading Up 3.8 %
NASDAQ:PDEX opened at $42.68 on Friday. The company has a market cap of $139.14 million, a P/E ratio of 27.71 and a beta of 0.39. Pro-Dex, Inc. has a twelve month low of $15.70 and a twelve month high of $46.50. The business has a 50 day moving average price of $29.24 and a two-hundred day moving average price of $22.72. The company has a quick ratio of 1.94, a current ratio of 3.41 and a debt-to-equity ratio of 0.36.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its earnings results on Thursday, September 5th. The medical instruments supplier reported $0.46 EPS for the quarter, topping the consensus estimate of $0.35 by $0.11. The business had revenue of $15.03 million during the quarter. Pro-Dex had a net margin of 9.17% and a return on equity of 16.74%. As a group, analysts expect that Pro-Dex, Inc. will post 1.42 EPS for the current fiscal year.
Hedge Funds Weigh In On Pro-Dex
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
From Darwin | Ad
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget!
We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
👉[Click here to get your FREE report delivered instantly!]
A number of large investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its position in shares of Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock valued at $240,000 after acquiring an additional 900 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Pro-Dex by 5.1% in the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock valued at $1,238,000 after purchasing an additional 3,067 shares in the last quarter. Bard Associates Inc. increased its position in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock worth $406,000 after purchasing an additional 2,031 shares during the last quarter. Finally, Perritt Capital Management Inc. increased its position in shares of Pro-Dex by 43.3% during the 1st quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier's stock worth $106,000 after purchasing an additional 1,813 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. Ascendiant Capital Markets boosted their price objective on shares of Pro-Dex from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, September 9th. StockNews.com upgraded Pro-Dex from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 7th.
Check Out Our Latest Analysis on Pro-Dex
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
